Vera jumps on additional mid-stage study data for kidney disease drug

Vera Therapeutics

28/10/2024 14:36

** Vera Therapeutics'  VERA.O  shares rise 14.1% to $46.88,
highest since April
** On Saturday, Vera reported additional data from a mid-stage
study testing its kidney disease drug, atacicept, as a potential
treatment for IgA nephropathy
    ** IgA nephropathy causes a protein called immunoglobulin A
to build up in the kidney
    ** At week 96, atacicept helped in reducing excess levels of
a protein in urine and stabilizing kidney function levels,
compared to placebo - VERA
** VERA said it will submit results from late-stage study of
atacicept in Q2 2025
    ** Including session's move, stock has more than tripled YTD

(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))